arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Oruka Therapeutics, Inc.

ORKA
$95.98 ▼ -5.50 (-5.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
88 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Weak
Neutral
auto_awesome

Analytical Summary

Oruka Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -3.6% ↗
FCF / Share None
Trailing P/E —
Price / Book 5.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

88-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-31.82M
↓ -29.5% —
FCF / Share Free cash flow per share
$-0.50
↓ -375.5% —

Health Breakdown

Returns ↑
27
Cash Quality ↓
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 23 years · 88 quarters